The necessity for insurance in research studies, including non-interventional studies and clinical trials, hinges on the potential risks and liabilities involved. Here’s a breakdown of why insurance may or may not be required for these different types of studies:
[1] Non-Interventional Studies = Non-interventional studies (observational studies) do not involve assigning specific treatments or healthcare interventions to participants. Instead, researchers observe participants in their normal setting or review existing records to gather data. Generally, non-interventional studies pose no more risk to participants than routine clinical practice (normal life) because the researchers do not influence the care or treatment the participants receive. As a result, insurance is not usually required for non-interventional studies (exceptions include Belgium). However, always check what the local insurance requirements are for your study type. Ignorance is never an excuse.
[2] Clinical Trials = In the context of medicinal products, clinical trials involve administering new drugs or off-label approved drugs to research participants. The risk of harm to the research participants is higher than would be encountered during normal (routine) clinical practice. As noted in the Declaration of Helsinki (§22) and ICH GCP (§5.8), the trial sponsor should “should address the costs of treatment of trial subjects in the event of trial-related injuries in accordance with the applicable regulatory requirement(s)”. Because of this, most (all?) countries require clinical trials to have insurance coverage as part of their regulatory approvals. This is to ensure that participants are protected and compensated for any trial-related injuries.
The key difference in the need for insurance between non-interventional studies and clinical trials lies in the level of risk and the potential for direct harm to the research participants. Clinical trials, especially those that test new medicinal products, carry inherent risks due to the unknown effects (in humans) of the treatments being tested. These risks necessitate a higher level of protection for both participants and researchers. On the other hand, non-interventional studies, which typically involve less direct interaction with participants and no alteration of their standard care, present lower risks, thereby reducing (negating) the need for insurance.
However, the specific requirements for insurance can vary widely depending on the country, the nature of the study, the type of data collected, and the potential risks involved. Researchers should always consult relevant regulations, guidelines, and regulatory bodies to ensure compliance with local laws regarding insurance coverage for their studies.
Share this story...
Real World Evidence (RWE) 201…THE END – A Landscape Analysis of Regional RWE Frameworks – The European Health Data Space and DARWIN-EU
RWE 201 - THE END - A Landscape Analysis of Regional RWE Frameworks - The European Health Data Space and DARWIN-EU In our real world evidence (RWE) 201 series [...]
Real World Evidence (RWE) – Event Horizon
RWE 201 - RWE Event Horizon The term "event horizon" in the context of pharmaceuticals, particularly when discussing the shift towards real-world evidence (RWE) in regulatory submissions, is metaphorically [...]
Real World Evidence (RWE) 201 – Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development
RWE 201 - Advancing Healthcare in Australia: Embracing Real-World Evidence and Data in Medicine Regulation and Development Australia has several real-world evidence (RWE) initiatives to support healthcare [...]
Real World Evidence (RWE) 201 – South Korea’s Pioneering Approach: Integrating Real-World Evidence in Healthcare and Drug Development
RWE 201 - South Korea's Pioneering Approach: Integrating Real-World Evidence in Healthcare and Drug Development South Korea has several initiatives to support healthcare and drug development using [...]
Real World Evidence (RWE) 201 – Taiwan: Integrating Real-World Evidence for Drug Development and Policy Making
RWE 201 - Taiwan: Integrating Real-World Evidence for Drug Development and Policy Making Taiwan has several real-world evidence (RWE) initiatives to support healthcare and drug development. Over the past [...]
Real World Evidence (RWE) 201 – Revolutionizing Healthcare in Japan: The Rise of Real-World Evidence in Drug Development
RWE 201 - Revolutionizing Healthcare in Japan: The Rise of Real-World Evidence in Drug Development Japan has several initiatives to support healthcare and drug development using real-world evidence (RWE). [...]